

Author Index

- Abramovitz, A.S., see Spruance, S.L. (28) 39
 Anderson, K.P., see Azad, R.F. (28) 101
 Araneo, B.A., see Spruance, S.L. (28) 39
 Azad, R.F., Brown-Driver, V., Buckheit, Jr., R.W. and Anderson, K.P. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs (28) 101
 Bachelor, L., see King, R.W. (28) 13
 Bäckbro, K., see Zhang, H. (28) 331
 Balzarini, J., see Reymen, D. (28) 343
 Barnard, D.L., Fairbairn, D.W., O'Neill, K.L., Gage, T.L. and Sidwell, R.W. Anti-human cytomegalovirus activity and toxicity of sulfonated anthraquinones and anthraquinone derivatives (28) 317
 Barnett, B.B., Smee, D.F., Malek, S.M. and Sidwell, R.W. Selective cytotoxicity towards cytomegalovirus-infected cells by immunotoxins consisting of gelonin linked to anti-cytomegalovirus antibody (28) 93
 Beauverline, J.M., see Tomai, M.A. (28) 253
 Beutner, K.R. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy (28) 281
 Blasecki, J.W., see Dicker, I.B. (28) 213
 Brennan, T.M., see Taylor, D.L. (28) 159
 Bridges, C.G., see Taylor, D.L. (28) 159
 Brown-Driver, V., see Azad, R.F. (28) 101
 Buckheit, Jr., R., see Hollingshead, M. (28) 265
 Buckheit, Jr., R.W., see Azad, R.F. (28) 101
 Cai, S., see Ghiasi, H. (28) 147
 Cardin, A.D., see Taylor, D.L. (28) 159
 Chokekijchai, S., Shirasaka, T., Weinstein, J.N. and Mitsuya, H. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI (28) 25
 Chousterman, S., see Crance, J.-M. (28) 69
 Chu, C.K., see Mar, E.-C. (28) 1
 Crance, J.-M., Lévêque, F., Chousterman, S., Jouan, A., Trépo, C. and Deloince, R. Antiviral activity of recombinant interferon- α on hepatitis A virus replication in human liver cells (28) 69
 Daynes, R.A., see Spruance, S.L. (28) 39
 Decker, W., see Hollingshead, M. (28) 265
 De Clercq, E., see Reymen, D. (28) 343
 Deloince, R., see Crance, J.-M. (28) 69
 Dicker, I.B. and Seetharam, S. Herpes simplex type 1 : *lacZ* recombinant viruses. I. Characterization and application to defining the mechanisms of action of known antiherpes agents (28) 191
 Dicker, I.B., Blasecki, J.W. and Seetharam, S. Herpes simplex type 1 : *lacZ* recombinant viruses. II. Microtiter plate-based colorimetric assays for the discovery of new antiherpes agents and the points at which such agents disrupt the viral replication cycle (28) 213
 Dvořáková, H., see Reymen, D. (28) 343
 Elder, C., see Hollingshead, M. (28) 265
 Evans, T.G., see Spruance, S.L. (28) 39
 Evans, T.G., see Spruance, S.L. (28) 57
 Fairbairn, D.W., see Barnard, D.L. (28) 317
 Gage, T.L., see Barnard, D.L. (28) 317
 Garber, S., see King, R.W. (28) 13
 Geniteau-Legendre, M., see Guillemard, E. (28) 175
 Gerin, J.L., see Korba, B.E. (28) 225
 Gerster, J.F., see Tomai, M.A. (28) 253
 Ghiasi, H., Cai, S., Slanina, S., Nesburn, A.B. and Wechsler, S.L. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge (28) 147

- Gibson, S.J., see Tomai, M.A. (28) 253
 Grever, M., see Hollingshead, M. (28) 265
 Griffin, D.E., see Hendrix, C.W. (28) 121
 Guillemard, E., Geniteau-Legendre, M., Kergot, R., Lemaire, G., Petit, J.F., Labarre, C. and Quero, A.M. Role of trehalose dimycolate-induced interferon- α/β in the restriction of encephalomyocarditis virus growth in vivo and in peritoneal macrophage cultures (28) 175
 Hansen, J.-E.S., see Lund, O.S. (28) 81
 Hendrix, C.W., Petty, B.G., Woods, A., Kuwahara, S.K., Witter, F.R., Soo, W., Griffin, D.E. and Lietman, P.S. Modulation of α -interferon's antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healthy volunteers (28) 121
 Hollingshead, M., Roberson, J., Decker, W., Buckheit, Jr., R., Elder, C., Malspeis, L., Mayo, J. and Grever, M. In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice (28) 265
 Holý, A., see Reymen, D. (28) 343
 Horton, V.L., see Tomai, M.A. (28) 253
 Hostettler, K.Y., see Xie, H. (28) 113
 Hui, Jr., F., see Kavlick, M.F. (28) 133
 Imbertson, L.M., see Tomai, M.A. (28) 253
 Jackson, R., see Taylor, D.L. (28) 159
 Jouan, A., see Crance, J.-M. (28) 69
 Kavlick, M.F., Shirasaka, T., Kojima, E., Pluda, J.M., Hui, Jr., F., Yarchoan, R. and Mitsuya, H. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (–)-2',3'-dideoxy-3'-thiacytidine (28) 133
 Kergot, R., see Guillemard, E. (28) 175
 Kikuchi, M., see Kim, H.-T. (28) 243
 Kim, D.-K., see Kim, H.-T. (28) 243
 Kim, H.-T., Kim, D.-K., Kim, Y.-W., Kim, K.H., Sugiyama, Y. and Kikuchi, M. Antiviral activity of 9-[[ethoxyhydroxyphosphinyl]methoxy]methoxy]guanine against cytomegalovirus and herpes simplex virus (28) 243
 Kim, K.H., see Kim, H.-T. (28) 243
 Kim, Y.-W., see Kim, H.-T. (28) 243
 King, R.W., Winslow, D.L., Garber, S., Scarnati, H.T., Bachelor, L., Stack, S. and Otto, M.J. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors (28) 13
 Kojima, E., see Kavlick, M.F. (28) 133
 Korba, B.A., see Xie, H. (28) 113
 Korba, B.E. and Gerin, J.L. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro (28) 225
 Kriesel, J.D., see Spruance, S.L. (28) 57
 Kuwahara, S.K., see Hendrix, C.W. (28) 121
 Labarre, C., see Guillemard, E. (28) 175
 Lemaire, G., see Guillemard, E. (28) 175
 Lévêque, F., see Crance, J.-M. (28) 69
 Lietman, P.S., see Hendrix, C.W. (28) 121
 Lin, J.-C., see Mar, E.-C. (28) 1
 Lind, P., see Zhang, H. (28) 331
 Liotta, D.C., see Xie, H. (28) 113
 Lund, O.S., Nielsen, J.O. and Hansen, J.-E.S. Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to *rev* (28) 81
 Malek, S.M., see Barnett, B.B. (28) 93
 Malspeis, L., see Hollingshead, M. (28) 265
 Mar, E.-C., Chu, C.K. and Lin, J.-C. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus (28) 1
 Mayo, J., see Hollingshead, M. (28) 265
 McKeough, M.B., see Spruance, S.L. (28) 39
 McKeough, M.B., see Spruance, S.L. (28) 57
 Miller, R.L., see Tomai, M.A. (28) 253
 Mishkin, E.M., see Spruance, S.L. (28) 39
 Mitsuya, H., see Chokekijchai, S. (28) 25
 Mitsuya, H., see Kavlick, M.F. (28) 133
 Morisawa, H., see Takase-Yoden, S. (28) 359
 Mullins, M.J., see Taylor, D.L. (28) 159
 Myhre, P.E., see Tomai, M.A. (28) 253
 Nadon, F., see Simard, C. (28) 303
 Naesens, L., see Reymen, D. (28) 343
 Nesburn, A.B., see Ghiasi, H. (28) 147
 Nielsen, J.O., see Lund, O.S. (28) 81
 Öberg, B., see Zhang, H. (28) 331
 O'Neill, K.L., see Barnard, D.L. (28) 317
 Otto, M.J., see King, R.W. (28) 13
 Petit, J.F., see Guillemard, E. (28) 175
 Petty, B.G., see Hendrix, C.W. (28) 121
 Pluda, J.M., see Kavlick, M.F. (28) 133
 Quero, A.M., see Guillemard, E. (28) 175
 Reiter, M.J., see Tomai, M.A. (28) 253
 Reymen, D., Naesens, L., Balzarini, J., Holý, A., Dvořáková, H. and De Clercq, E. Antiviral ac-

- tivity of selected acyclic nucleoside analogues against human herpesvirus 6 (28) 343
- Richman, D.D., see Xie, H. (28) 113
- Roberson, J., see Hollingshead, M. (28) 265
- Sahlberg, C., see Zhang, H. (28) 331
- Scarnati, H.T., see King, R.W. (28) 13
- Schinazi, R.F., see Xie, H. (28) 113
- Schinazi, R.F. and Yao, X. Hydrocephalus induction in mice infected with herpes simplex virus type 2 after antiviral treatment (28) 291
- Seetharam, S., see Dicker, I.B. (28) 191
- Seetharam, S., see Dicker, I.B. (28) 213
- Séguin, C., see Simard, C. (28) 303
- Shibahara, S., see Takase-Yoden, S. (28) 359
- Shirasaka, T., see Chokekijchai, S. (28) 25
- Shirasaka, T., see Kavlick, M.F. (28) 133
- Sidwell, R.W., see Barnett, B.B. (28) 93
- Sidwell, R.W., see Barnard, D.L. (28) 317
- Simard, C., Nadon, F., Séguin, C. and Trudel, M. Evidence that the amino acid region 124–203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection (28) 303
- Slanina, S., see Ghiasi, H. (28) 147
- Smee, D.F., see Barnett, B.B. (28) 93
- Soo, W., see Hendrix, C.W. (28) 121
- Spruance, S.L., Evans, T.G., McKeough, M.B., Thai, L., Araneo, B.A., Daynes, R.A., Mishkin, E.M. and Abramovitz, A.S. Th1/Th2-like immunity and resistance to herpes simplex labialis (28) 39
- Spruance, S.L., Kriesel, J.D., Evans, T.G. and McKeough, M.B. Susceptibility to herpes labialis following multiple experimental exposures to ultraviolet radiation (28) 57
- Stack, S., see King, R.W. (28) 13
- Sugiyama, Y., see Kim, H.-T. (28) 243
- Takase-Yoden, S., Shibahara, S., Morisawa, H. and Watanabe, R. Inhibition of neurotropic mouse retrovirus replication in glial cells by synthetic oligo(2'-O-methyl)ribonucleoside phosphorothioates (28) 359
- Tamulinas, C.B., see Tomai, M.A. (28) 253
- Taylor, D.L., Brennan, T.M., Bridges, C.G., Mullins, M.J., Tyms, A.S., Jackson, R. and Cardin, A.D. Potent inhibition of human immunodeficiency virus by MDL 101028, a novel sulphonic acid polymer (28) 159
- Thai, L., see Spruance, S.L. (28) 39
- Tomai, M.A., Gibson, S.J., Imbertson, L.M., Miller, R.L., Myhre, P.E., Reiter, M.J., Wagner, T.L., Tamulinas, C.B., Beaurline, J.M., Gerster, J.F. and Horton, V.L. Immunomodulating and antiviral activities of the imidazoquinoline S-28463 (28) 253
- Trépo, C., see Crance, J.-M. (28) 69
- Trudel, M., see Simard, C. (28) 303
- Tyms, A.S., see Taylor, D.L. (28) 159
- Unge, T., see Zhang, H. (28) 331
- Voronkov, M., see Xie, H. (28) 113
- Vrang, L., see Zhang, H. (28) 331
- Wagner, T.L., see Tomai, M.A. (28) 253
- Watanabe, R., see Takase-Yoden, S. (28) 359
- Wechsler, S.L., see Ghiasi, H. (28) 147
- Weinstein, J.N., see Chokekijchai, S. (28) 25
- Winslow, D.L., see King, R.W. (28) 13
- Witter, F.R., see Hendrix, C.W. (28) 121
- Woods, A., see Hendrix, C.W. (28) 121
- Xie, H., Voronkov, M., Liotta, D.C., Korba, B.A., Schinazi, R.F., Richman, D.D. and Hostetler, K.Y. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B- and HIV-1-infected cells (28) 113
- Yao, X., see Schinazi, R.F. (28) 291
- Yarchoan, R., see Kavlick, M.F. (28) 133
- Zhang, H., Vrang, L., Bäckbro, K., Lind, P., Sahlberg, C., Unge, T. and Öberg, B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127 (28) 331